Structures of gamma-aminobutyric acid (GABA) aminotransferase, a pyridoxal 5'-phosphate, and [2Fe-2S] cluster-containing enzyme, complexed with gamma-ethynyl-GABA and with the antiepilepsy drug vigabatrin
about
Redox-switch modulation of human SSADH by dynamic catalytic loopStructural Characterization of the Mycobacterium tuberculosis Biotin Biosynthesis Enzymes 7,8-Diaminopelargonic Acid Synthase and Dethiobiotin Synthetase,Structural Determinants of the -Selectivity of a Bacterial AminotransferaseStructures of a γ-aminobutyrate (GABA) transaminase from thes-triazine-degrading organismArthrobacter aurescensTC1 in complex with PLP and with its external aldimine PLP–GABA adductCrystal structure of Bacillus subtilis GabR, an autorepressor and transcriptional activator of gabTFrom protein structure to function via single crystal optical spectroscopyPoisoning pyridoxal 5-phosphate-dependent enzymes: a new strategy to target the malaria parasite Plasmodium falciparumClinical trial of vigabatrin as adjunctive therapy in children with refractory epilepsy.A neuron-glia interaction involving GABA transaminase contributes to sleep loss in sleepless mutantsThe 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile sSynthesis of quaternary amino acids bearing a (2'Z)-fluorovinyl alpha-branch: potential PLP enzyme inactivators.Protein-Templated Fragment Ligations-From Molecular Recognition to Drug Discovery.Mechanisms and structures of vitamin B(6)-dependent enzymes involved in deoxy sugar biosynthesis.Targeting cystalysin, a virulence factor of treponema denticola-supported periodontitis.Mechanism of inactivation of γ-aminobutyric acid aminotransferase by (1S,3S)-3-amino-4-difluoromethylene-1-cyclopentanoic acid (CPP-115)Use of knowledge-based restraints in phenix.refine to improve macromolecular refinement at low resolution.Mechanism of Inactivation of GABA Aminotransferase by (E)- and (Z)-(1S,3S)-3-Amino-4-fluoromethylenyl-1-cyclopentanoic Acid.Probing the steric requirements of the γ-aminobutyric acid aminotransferase active site with fluorinated analogues of vigabatrin.Synthesis and evaluation of novel aromatic substrates and competitive inhibitors of GABA aminotransferase.A retro-evolution study of CDP-6-deoxy-D-glycero-L-threo-4-hexulose-3-dehydrase (E1) from Yersinia pseudotuberculosis: implications for C-3 deoxygenation in the biosynthesis of 3,6-dideoxyhexoses.Enantiomers of 4-amino-3-fluorobutanoic acid as substrates for gamma-aminobutyric acid aminotransferase. Conformational probes for GABA bindingVigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.Ornithine aminotransferase versus GABA aminotransferase: implications for the design of new anticancer drugs.Privileged Electrophile Sensors: A Resource for Covalent Drug Development.Chemogenomics of pyridoxal 5'-phosphate dependent enzymes.Use of Fluorinated Functionality in Enzyme Inhibitor Development: Mechanistic and Analytical AdvantagesSynchronization by food access modifies the daily variations in expression and activity of liver GABA transaminase.A formal [3,3]-sigmatropic rearrangement route to quaternary alpha-vinyl amino acids: use of allylic N-PMP trifluoroacetimidates.Examination of the new alpha-(2'Z-fluoro)vinyl trigger with lysine decarboxylase: the absolute stereochemistry dictates the reaction course.Vitamin B6-dependent enzymes in the human malaria parasite Plasmodium falciparum: a druggable target?Cloning, purification, crystallization and preliminary X-ray crystallographic analysis of the biosynthetic N-acetylornithine aminotransferases from Salmonella typhimurium and Escherichia coliPLP and GABA trigger GabR-mediated transcription regulation in Bacillus subtilis via external aldimine formationOverexpression, purification and crystallization of lysine epsilon-aminotransferase (Rv3290c) from Mycobacterium tuberculosis H37Rv.Docking studies of phthalimide pharmacophore as a sodium channel blocker.Loss-of-function mutations in ISCA2 disrupt 4Fe-4S cluster machinery and cause a fatal leukodystrophy with hyperglycinemia and mtDNA depletion.Metabolic pathway of 6-aminohexanoate in the nylon oligomer-degrading bacterium Arthrobacter sp. KI72: identification of the enzymes responsible for the conversion of 6-aminohexanoate to adipate.Design and Mechanism of (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a Highly Potent γ-Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Addiction.Molecular dynamics simulations of apo, holo, and inactivator bound GABA-at reveal the role of active site residues in PLP dependent enzymes.Design, synthesis, and biological evaluation of hydrazone incorporated 1,2,4-triazines as anticonvulsant agents.Theoretical studies on the inactivation mechanism of γ-aminobutyric acid aminotransferase.
P2860
Q27654216-59496048-97F5-40F4-A7D8-7760350A3292Q27662522-A1FFCFF8-A143-4E1B-A514-6DB2E0AC4F39Q27670553-DA7F25F2-4F13-4707-82D3-5EC4F3ADB852Q27673804-EC8994A5-B108-4B3B-A4A7-BEF984A5BE1EQ27680367-3C51F346-CC13-487A-8CED-931D6B213D59Q28084584-B5F4816A-546A-4241-A447-C1471EF0F0EDQ28474722-4E67AA1B-700D-4E59-8C09-BAB1D7ED0B60Q33628299-A571DDC6-9A8E-44B8-A247-61403F36763DQ34207469-DE1D521F-B32D-4A0A-9BF0-AEF4C4042725Q34240602-3A97E01B-2D36-476B-B70D-E439964F61C7Q34321736-E0CEBB6F-035B-46AF-BC83-C8B69927DF75Q34549950-4B4F8E9D-5588-4FA9-BE9F-8EAAAC72B1EFQ35046495-B1673B97-3C31-497B-9151-72EB05BA5904Q35116929-89DB5C3B-F4F2-404A-9096-62BB549629D4Q35157592-F5F0ED98-EBDA-4F68-B643-B9031D40D042Q35878822-F6FA235D-FA04-40CC-97BF-AE659F4AA9E7Q36074460-9441948F-0950-48B1-AF53-67CF66BCAF5CQ36586336-F109D587-897D-454D-8AF1-E4F8350D42BDQ36784747-E7EFEC23-1521-42DC-9C98-499C72496C4BQ36835472-E9E76092-0438-4AEC-B3A5-617B232D5913Q36944163-815E745A-03F5-4F7F-B958-424310947332Q37642768-32997CE3-E99E-4BB0-AF3B-DA2E142AD0A5Q38242012-FE0FEF06-9943-4CAD-851A-54DCFABF5729Q38710055-16047037-7CBE-45A0-9CBD-E5278E215831Q39674260-3368E4EC-AAD2-4249-BB58-484B65DCCBDFQ41095327-38D314DA-8F12-4818-AE75-65A924E2BB6EQ41185872-2A522D4D-0D26-45C7-8D5D-E2D30F1BD015Q41737383-7EB24A7A-B7A8-4927-951B-DBCBB5EF9212Q41860982-DE2B2D79-256A-4B88-AA58-394E198C7E27Q41911094-9554DDC4-4A5C-4252-B242-05CE9970FA7BQ41916639-FBB8A214-7ECF-4F82-9474-F2432901D1ACQ42140394-E07F2FD9-89A0-470A-AF08-2802036A4600Q42254173-39968AF9-70DA-45CB-85FC-975C42EC9F65Q42939077-E7FC659A-EB74-4050-8E2B-DFEF05206329Q47214684-938AE2CA-EB1F-4301-AADA-96A518C83A05Q47300635-F5CE60B2-7F6C-497D-90F8-117F7B2BEDBFQ47832021-AC94F38A-636C-4702-B56A-665F8B9106F2Q48065730-5C4405DA-2EA8-4C28-8694-22D4754EBC2FQ48205696-3ADDC7CC-5FCC-46C9-A92A-98E19160A8C0Q51560566-4ECFCDBA-0037-4C60-B46F-27BD3F52CDB5
P2860
Structures of gamma-aminobutyric acid (GABA) aminotransferase, a pyridoxal 5'-phosphate, and [2Fe-2S] cluster-containing enzyme, complexed with gamma-ethynyl-GABA and with the antiepilepsy drug vigabatrin
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Structures of gamma-aminobutyr ...... e antiepilepsy drug vigabatrin
@ast
Structures of gamma-aminobutyr ...... e antiepilepsy drug vigabatrin
@en
Structures of gamma-aminobutyr ...... e antiepilepsy drug vigabatrin
@nl
type
label
Structures of gamma-aminobutyr ...... e antiepilepsy drug vigabatrin
@ast
Structures of gamma-aminobutyr ...... e antiepilepsy drug vigabatrin
@en
Structures of gamma-aminobutyr ...... e antiepilepsy drug vigabatrin
@nl
prefLabel
Structures of gamma-aminobutyr ...... e antiepilepsy drug vigabatrin
@ast
Structures of gamma-aminobutyr ...... e antiepilepsy drug vigabatrin
@en
Structures of gamma-aminobutyr ...... e antiepilepsy drug vigabatrin
@nl
P2093
P2860
P50
P356
P1476
Structures of gamma-aminobutyr ...... e antiepilepsy drug vigabatrin
@en
P2093
Caroline Peneff
Francesco Bossa
Paola Storici
Richard B Silverman
P2860
P304
P356
10.1074/JBC.M305884200
P407
P577
2004-01-02T00:00:00Z